Success Stories: Liver Therapeutics Leader Gains EB1A Approval Through NAILG’s Proven Legal Support

Client’s Testimonial:

“The attorney was very prompt in answering all my questions within 24 hours. The drafting of the petition went very smoothly.”

On February 27^th, 2025, we received another EB1A (Alien of Extraordinary Ability) approval for a Postdoctoral Research Associate in the Field of Liver Disease (Approval Notice).

General Field: Liver Disease

Position at the Time of Case Filing: Postdoctoral Research Associate

Country of Origin: India

State of Residence at the Time of Filing: Missouri

Approval Notice Date: February 27^th, 2025

Processing Time: 1 year, 1 month, 11 days

Case Summary:

In a significant achievement, an EB1A (Extraordinary Ability) petition has been approved for a pioneering liver disease researcher whose expertise spans hepatotoxicological evaluation, liver-targeted therapeutics, and regenerative medicine. With an unwavering commitment to improving global health outcomes, this researcher has advanced the understanding of liver toxicity, non-alcoholic fatty liver disease (NAFLD), and novel gene delivery systems, areas that hold far-reaching medical importance.

Leading Innovation in Hepatology

Over the course of his career, the researcher has led groundbreaking studies that explore the use of silibinin to counter drug-induced liver toxicity, uncovered mitochondrial dysfunctions in NAFLD, investigated the potential of mesenchymal stem cells in treating liver injuries, and introduced a novel double-stranded mRNA delivery system for liver therapies. These innovations have not only advanced scientific understanding but also offered promising new strategies for the treatment of liver-related diseases.

A Strong Record of Peer-Validated Contributions

His academic contributions include 17 peer-reviewed journal articles (with 9 first-authored) and 6 abstracts (4 of them first-authored). His work has been cited 209 times in scientific literature, with influence extending to researchers across 34 countries. According to Google Scholar, this places him in the top 1% of researchers publishing on liver enzymes over the past ten years, an indicator of both scholarly excellence and real-world relevance.

Recognized Leadership in the Scientific Community

Further reinforcing his leadership, the researcher has completed over 50 peer reviews for prominent academic journals, reflecting his trusted expertise and active role in shaping the field. His projects have been funded by a variety of prestigious institutions, including the National Institutes of Health (NIH), the Department of Veteran’s Affairs (VA), the University Grants Commission (UGC), and the Indian Council of Medical Research (ICMR).

Endorsed by Experts in the Field

A testimonial submitted with the petition emphasized his critical role in advancing liver health:

“As illustrated in this letter, [Client] is a unique talent in the field of hepatology whose work has positive implications for those taking anti-retroviral and anti-tubercular medications. His fulfilment of peer review duties only reinforces his active participation in shaping the future of the field.”

Approval and Future Directions

The EB1A petition was successfully prepared and submitted with strategic guidance from the North America Immigration Law Group (NAILG). By presenting a compelling narrative backed by strong evidence of scientific impact, NAILG helped ensure the petition’s approval.

With this milestone achieved, the researcher is now poised to continue advancing liver disease research in the U.S., bringing innovative, life-saving solutions to the forefront of modern medicine.

North America Immigration Law Group (Chen Immigration Law Associates) is a U.S. immigration law firm dedicated to representing corporations, research institutions, and individuals from all 50 U.S. states regarding I-140 immigration petitions. We specialize in employment-based immigration petition and have a proven record of high success rate for the categories of: EB2-NIW (National Interest Waiver), EB1-A (Alien of Extraordinary Ability), EB1-B (Outstanding Researcher/Professor) and O-1 (Alien of Extraordinary Ability).

Our Ten Thousand I-140 Approvals Provide Unprecedented Insight into the USCIS Adjudication Trend

With more than 58,000 EB-1A, EB-1B, EB-2 NIW and O-1 cases approved, we have first hand information on the manner in which the USCIS adjudicate I-140 cases. As the USCIS has constantly changed its adjudication standards for the EB-1A, EB-1B and EB-2 NIW categories, our firm's huge database of successful cases gives you unprecedented insight to USCIS adjudication trends. We carefully analyze the data for all of our cases and apply the results of our analyses toward giving our clients up-to-date advice and adapting our strategies such that we remain on par with the ever-shifting landscape of immigration law in the U.S. With us, you will always have access to important updates, strategies, and information so that you can make the most informed decisions about your case.

We Have Helped Hundreds and Thousands of Clients with Credentials and Backgrounds Similar to Yours

With our exceedingly large number of successful petitions, no matter what credentials you have, no matter your background and field of expertise, no matter your visa status or nationality, chances are we have helped hundreds or even thousands of clients just like you. Our clients are usually impressed with how well we understand their research and work. Our insight and understanding stems from the fact that we have handled many cases with elements similar to yours already, and this helps us devise the best strategies for each individual petition.

Vast Majority of Clients Came to Us Because of Referrals

For years, our firm has attracted new clients based solely on word of mouth, recommendations, and the positive collaboration experiences shared with them by their friends and family. We take pride in our reputation and work hard to ensure that we provide a green card application experience that our clients are happy to share with their friends and colleagues. That is how our cumulative total of approved cases grew from 600 in 2013 to over 58,000 in 2025.